NNNobuhiro Nitori

Nobuhiro Nitori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nobuhiro Nitori has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Complete remission of peritoneal dissemination of colon cancer by alternate‑day S‑1 and oxaliplatin plus bevacizumab treatment and maintenance chemotherapy comprising alternate‑day S‑1 plus bevacizumab: A case report

    by Nobuhiro Nitori, Ayu Kato, Tomoaki Deguchi, Jumpei Nakadai, Ayako Tada, Makoto Takahashi, Rumiko Umeda, Naoteru Miyata, Mikinori Kataoka, Tomohisa Kadomura, et al.

    A 56‑year‑old man diagnosed with sigmoid colon cancer underwent sigmoid colectomy. Nine months later, his serum carcinoembryonic antigen (CEA) level had increased, and the diagnosis of recurrent peritoneal dissemination was made based on positron emission tomography/computed tomography (PET/CT) findings. Although systemic chemotherapy comprising S‑1 and oxaliplatin (SOX) plus bevacizumab was initiated, severe diarrhea occurred on day 4 of the second cycle despite reduction in S‑1 dose. By changing the daily oral intake schedule for S‑1 to an alternate‑day intake from the third cycle (modified SOX plus bevacizumab), the patient was able to continue undergoing chemotherapy without any adverse gastrointestinal effects. All tumors disappeared after four cycles, and the patients received eight cycles of modified SOX plus bevacizumab followed by maintenance chemotherapy comprising alternate‑day S‑1 plus bevacizumab. Maintenance chemotherapy was discontinued after 17 cycles owing to adverse events, including thrombocytopenia, corneal and lacrimal duct disorders, and hyperbilirubinemia. The patient has been radiographically confirmed to be in remission for 5 years without any recurrence, and his serum CEA level has been within normal range for >3 years. To conclude, compared with the conventional consecutive treatment, alternate‑day SOX plus bevacizumab treatment may reduce the adverse effects of these chemotherapeutic drugs.


  • A Case of Complete Rectal Prolapse Requiring Emergency Operation with Severe Anemia by Frequent Hematochezia

    by Jumpei Nakadai, Nobuhiro Nitori, Ayako Tada, Shinpei Matsui, Ayu Kato, Tomohisa Kadomura, Mikinori Kataoka, Tomoaki Deguchi, Yoshihiko Takao

    症例は37歳,女性.3年前より血便を認め,2ヵ所の病院で消化管精査を行ったが出血源不明であり,精査目的で当院消化器センターを紹介受診した.来院時Hb 6.0g/dlと高度貧血を認めたために輸血を行った.当院でも下部消化管内視鏡を施行したが,出血源を認めなかった.その後も血便が連日続き,外科に紹介となった.詳細に問診を行うと排便後肛門から直腸の脱出があることがわかり,怒責診で完全直腸脱を認めた.粘膜の鬱血で静脈性出血を認め,高度貧血もきたしていたため緊急性が高いと判断し,緊急で根治術を行った.腹腔鏡で観察するとダグラス窩に深いcul de sacを認め,直腸脱として矛盾はなかった.腹腔鏡下直腸固定術および腹腔鏡下骨盤底形成術を施行した.術後経過は良好で,再発を認めていない.今回,繰り返す血便により高度貧血をきたし,緊急手術を要した完全直腸脱の1例を経験したため,文献的考察を加えて報告する.

    • 11 April 2014
      • Vol. 60  (128) , 2133-6

    Modified gastroduodenostomy in laparoscopy-assisted distal gastrectomy: a 'tornado' anastomosis.

    by Keisuke Kubota, Junko Kuroda, Masashi Yoshida, Akihiro Okada, Nobuhiro Nitori, Masaki Kitajima

    This study was to examine the utility of a modified double-stapling end-to-end gastroduodenostomy method ('Tornado' anastomosis) compared to a method with an additional gastrotomy ('Anterior Incision' method) in laparoscopy-assisted distal gastrectomy. Forty-two patients with gastric cancer who underwent laparoscopy-assisted distal gastrectomy were analyzed retrospectively. Billroth-I using an additional gastrotomy was performed in 24 patients (AI group) and Billroth-I without an additional gastrotomy was performed in 18 (TOR group). Clinicopathological features, operative outcomes (lymph node dissection, operative time, operative blood loss) and postoperative outcomes (complications, postoperative hospital stay, and body weight loss at one year after surgery) were evaluated and compared between groups. Operative time was significantly shorter in the TOR group (251 min) than in the AI group (282 min) (p < 0.01). There were no statistically significant differences in operative blood loss, postoperative complications, and hospital stay between the 2 study groups. Body weight loss at one year after surgery was -5.8 kg in the TOR group and -6.5 kg in the AI group, without a statistically significant difference. Completion time for Billroth-I anastomosis was significantly shorter with Tornado anastomosis than with the Anterior Incision method, with safety equal between the two methods.

  • Successful treatment of non-occlusive mesenteric ischemia (NOMI) using the HyperEye Medical System™ for intraoperative visualization of the mesenteric and bowel circulation: report of a case

    by Nobuhiro Nitori, Tomoaki Deguchi, Keisuke Kubota, Masashi Yoshida, Ayu Kato, Masayuki Kojima, Tomohisa Kadomura, Akihiro Okada, Juri Okamura, Michiya Kobayashi, et al.

    Non-occlusive mesenteric ischemia (NOMI), leading to intestinal gangrene without a demonstrable occlusion in the mesenteric artery, is a rare condition with extremely high mortality. We report a case of NOMI diagnosed preoperatively by computed tomography and treated successfully with surgery, assisted by indocyanine green (ICG) fluorescence in the HyperEye Medical System (HEMS), a new device that can simultaneously detect color and near-infrared rays under room light. This allowed for precise intraoperative evaluation of the mesenteric and bowel circulation. Although the necrotic bowel wall of the distal ileum and the segmental ischemia of the jejunum were visible, the jejunum was finally preserved because perfusion of ICG fluorescence was confirmed. The patient, an 84-year-old man, had an uneventful postoperative course and is alive without critical illness 8 months after surgery. We report this case to demonstrate the potential effectiveness of HEMS during surgery for NOMI.


  • A case of duplicated vermiform appendix

    by Takashi Fujii, Mikinori Kataoka, Sho Anzai, Tomoaki Shirasaki, Hidekazu Ikemiyagi, Kazuhisa Mabuchi, Shinji Suzuki, Akihiro Okada, Ayu Katou, Tomoaki Deguchi, et al.


    • 1 November 2011
      • Vol. 31  (11) , 3983-9

    Clinical experience with chemoradiotherapy comprising S-1 plus low-dose cisplatin in a patient with stage IV anal cancer.

    by Nobuhiro Nitori, Yutaro Kato, Ayu Kato, Tomoaki Deguchi, Akihiro Okada, Masayuki Kojima, Junko Kuroda, Tomohisa Kadomura, Keisuke Kubota, Nobuto Origuchi, et al.

    We report a case of anal cancer in a 58-year-old woman who complained of narrow, bloody stools and anal pain. Physical examination revealed anal stenosis associated with a circular mass arising in the anal canal. Histological examination of biopsy specimens confirmed a diagnosis of moderately differentiated squamous cell carcinoma. Enhanced computed tomography revealed anal cancer invading the levator ani and the vagina, with lymph-node, multiple hepatic, and pulmonary metastases. The patient received two cycle of chemoradiotherapy with S-1 plus low-dose cisplatin with rest for 4 weeks, leading to complete response of the primary lesion and a partial response of the metastatic lesions. Each cycle included oral S-1 (120 mg/body; day 1-21), cisplatin (10 mg/body; day 1-5, 8-12) and radiotherapy (2 Gy/day; day 1-5, 8-12, 15-19). Adverse effects of treatment were mild perineal skin erosion and mild appetite loss, but no hematologic toxicity. Although the patient died 16 months after first admission, chemoradiotherapy with S-1 plus cisplatin is potentially effective for the management of advanced anal cancer.


    • 1 July 2010
      • Vol. 68  (7) , 1215-23

    [The history of endoscopy and endoscopic surgery in Japan].

    by Masaki Kitajima, Masashi Yoshida, Keisuke Kubota, Yutaro Kato, Junko Kuroda, Nobuhiro Nitori, Tomoaki Deguchi

    In Japan, the first gastro camera was introduced as a trial in 1950, and has improved continuously. On the other hand, in Europe, it was earlier that the first laparoscopic examination was tried in 1901 by Kelling. After that, laparoscopic surgery was developed by originating in a gynecologic surgery. The historical moment came in 1987, Prof. Mouret has succeeded in laparoscopic cholecystectomy, and for 20 years, endoscopic has been developing rapidly with progress of related devices. This remarkable advance is based on the collaboration between basic medicine and clinical medicine, in other words, the concept of engineering based medicine.

    • 5 February 2009
      • Vol. 28, 3593-9

    Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis.

    by Shota Takano, Tetsuro Kubota, Hideki Nishibori, Hirotoshi Hasegawa, Yoshiyuki Ishii, Nobuhiro Nitori, Hiroki Ochiai, Koji Okabayashi, Yuko Kitagawa, Masahiko Watanabe, et al.

    Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a member of the steroid receptor superfamily. Liganded PPARgamma can inhibit cancer cell proliferation. The in vitro and in vivo inhibitory effect of the synthetic ligands, ciglitazone (CGZ) and pioglitazone (PGZ), on human colon cancer was investigated. Cell proliferation and the expression of PPARgamma, cyclooxygenase (COX)-2 and cyclin D1 were assessed in colon cancer cells treated with CGZ or PGZ. After subcutaneous or splenic inoculation of severe combined immunodeficient (SCID) mice using colon cancer HT-29 and SW480 cells, PGZ was administered orally and tumor growth inhibition was assessed by xenograft volume. The COX-2, cyclin D1 and PPARgamma expression in the HT-29 cells was evaluated. Cultured HT-29 and SW480 cells expressed PPARgamma and proliferation was inhibited by CGZ and PGZ. Oral PGZ inhibited xenograft tumor growth and liver metastases in the SCID mouse and suppressed expression of COX-2 and cyclin D1 in HT-29 cells. PGZ down-regulates COX-2 and cyclin D1 and inhibits colon cancer proliferation and liver metastasis, making PPARgamma a candidate target for the treatment/prevention of colon cancer metastasis.


  • A Case of Sister Mary Joseph's Nodule

    by Masashi Tsuruta, Hirotoshi Hasegawa, Hideki Nishibori, Yoshiyuki Ishii, Takashi Endo, Nobuhiro Nitori, Koji Okabayashi, Fumitaka Asahara, Makio Mukai, Masaki Kitajima

    症例は70歳の男性で, 下腹部痛および臍部腫瘤を主訴に当院皮膚科を受診. 臍上部に発赤, 圧痛を伴う1.0cm大の硬結を触知し組織生検にて腺癌の臍転移が疑われた. 内科での全身精査にてS状結腸に2型の進行癌を認めた. その他の遠隔転移は認めず原発巣と同時に臍部転移巣を完全切除した. 病理組織学的にS状結腸癌臍転移と診断された. テガフール・ウラシル内服による補助化学療法施行するも, 術後6か月目に腹壁転移を認め, 9か月目に癌死した. 内臓悪性疾患の臍転移はSister Mary Joseph's noduleと言われ, 予後不良で発見から死亡まで1年以内との報告も多いが, 原発巣および臍転移部の外科的切除で予後が改善されたという報告もある. 臍部腫瘤に関しては内臓悪性疾患の臍転移も念頭におきながら精査する必要があると思われた.